Association of histologic regression with a favorable outcome in patients with stage 1 and stage 2 cutaneous melanoma

Source: MDLinx, February 2021

In patients with primary cutaneous melanoma, this study was undertaken to investigate if histologically confirmed regression was correlated with better or worse survival.

Researchers analyzed data from two large cohorts of adults (one in the Netherlands and the other in Australia) with histologically proven, stage 1 and 2 primary, invasive cutaneous melanoma with known regression status treated between 2000 and 2014, with median follow-up times of 4.5 years for the Dutch cohort and 11.1 years for the Australian cohort.

They enrolled 17,271 Dutch patients and 4,980 Australian patients.